PATENT CLAIM ANALYSIS

Application Number: 16040684
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["514", "006200"]

Abstract:
The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.

Claim (Index 3):
The insulin derivative of  claim 1 , the derivative being\n A22N \u03f5 -16-(2,3-difluoro-4-boronobenzoylamino)hexadecanoyl B29N(epsilon)-16-(2,3-difluoro-4-boronobenzoylamino)hexadecanoyl A14E A22K B25H desB30 human insulin; B29N \u03f5 -16-(2,3-difluoro-4-boronobenzoylamino)hexadecanoyl-\u03b3-L-glutamyl desB30 human insulin; B29N 68 -16-(3,5-diboronobenzoylamino)hexadecanoyl desB30 human insulin; B29N 68 -16-(2,3-difluoro-4-boronobenzoylamino)hexadecanoyl desB30 human insulin; B29N 68 -16-(3-fluoro-4-boronobenzoylamino)hexadecanoyl desB30 human insulin; B29N 68 -16-(3-fluoro-4-boronobenzoylamino)hexadecanoyl-\u03b3-L-glutamyl desB30 human insulin; B29N 68 -16-(2,6-difluoro-4-boronobenzoylamino)hexadecanonyl desB30 human insulin; A22N 68 -16-(3,5-diboronobenzoylamino)hexadecanoyl A22K B29R desB30 human insulin; A22N 68 -16-(3,5-diboronobenzoylamino)hexadecanoyl A14E A22K B25H B29R desB30 human insulin; A22N 68 -16-(3,5-diboronobenzoylamino)hexadecanoyl-L-\u03b3-glutamyl A14E A22K B25H B29R desB30 human insulin; B29-N \u03f5 -{4-[16-(3-boronobenzenesulfonylamino)hexadecanoylsulfamoyl]butanoyl}desB30 human insulin; A22N 68 -15-(3,5-diboronobenzoylamino)pentadecanoyl B29N 68 -15-(3,5-diboronobenzoylamino)-pentadecandioyl A14E A22K B25H desB30 human insulin; A22N \u03f5 -15-(3,5-diboronobenzoylamino)pentadecanoyl B29N \u03f5 -15-(3,5-diboronobenzoylamino)pentadecandioyl A22K desB30 human insulin; B29N 68 -16-(3,5-diboronobenzoylamino)hexadecanoyl-L-\u03b3-glutamyl A14E B25H desB30 human insulin; A22N \u03f5 -15-(3,5-diboronobenzoylamino)pentadecanoyl-\u03b3-L-glutamyl B29N \u03f5 -15-(3,5-diboronobenzoylamino)pentadecandioyl-\u03b3-L-glutamyl A14E A22K B25H desB30 human insulin; B29N \u03f5 -{4-{16-(3-boronobenzenesulfonylamino)hexadecanoylsulfamoyl]butanoyl}A14E B25H desB30 human insulin; A22N \u03f5 -12-(3,5-diboronobenzoylamino)dodecanoyl B29N \u03f5 -12-(3,5-diboronobenzoylamino)dodecandioyl A14E A22K B25H desB30 human insulin; A22N \u03f5 -12-(3,5-diboronobenzoylamino)dodecanoyl B29N \u03f5 -12-(3,5-diboronobenzoylamino)-dodecandioyl A22K desB30 human insulin; B29N \u03f5 -16-(2,3-difluoro-4-boronobenzoylamino)hexadecanoyl A14E B25H des B30 human insulin; A22N \u03f5 -12-(3,5-diboronobenzoylamino)dodecanoyl-gamma-L-glutamyl B29N \u03f5 -12-(3,5-diboronobenzoylamino)dodecandioyl-gamma-L-glutamyl A22K desB30 human insulin; and A22N \u03f5 -12-(3,5-diboronobenzoylamino)dodecanoyl-gamma-L-glutamyl B29N \u03f5 -12-(3,5-diboronobenzoylamino)dodecandioyl-gamma-L-glutamyl A14E A22K B25H desB30 human insulin B29N \u03f5 -16-(2,6-difluoro-4-boronobenzoylamino)pentadecanoyl A14E B25H desB30 human insulin; B29N \u03f5 -16-(2,6-difluoro-4-boronobenzoylamino)hexadecanoyl A14E B25H desB30 human insulin; or B29N \u03f5 -16-(4-boronobenzoylamino)hexadecanoyl A14E B25H desB30 human insulin.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 95.0
- Lexical Diversity: 1.15
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12935438', '14126215', '13224538', '12673516', '15121206']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8353616299529366
- 35 USC 102 Novelty (BERT): 0.5809996591256064
- Combined Prediction Score: 0.8099254328702036
- Mean Citation Score: 445.473044
- Max Citation Score: 501.0652
- Similarity Product: 413.14353101582526

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test